Combination of Chlorthalidone, Amlodipine, and Telmisartan is effective and safe to improve the blood pressure-lowering effect in people having essential hypertension.

Individuals with essential hypertension were examined to determine the safety and effectiveness of low-dose triple combinations of Chlorthalidone, Telmisartan, and Amlodipine.

Following a two-week run-in with a placebo, 176 volunteers were randomly allocated to one of seven treatment groups (quarter-dose combination, placebo, half-dose combination, third-dose combination, 5 mg Amlodipine, 10 mg Amlodipine, and 80 mg Telmisartan) and given the assigned study medication orally for eight weeks. Alteration in the mean sitting systolic blood pressure at week 8 served as the primary effectiveness outcome in this clinical trial.

In comparison to the placebo and 5 mg Amlodipine groups, the mean sitting diastolic blood pressure and the mean sitting systolic blood pressure in the half-dose and quarter-dose groups were considerably reduced. Similar blood pressure-lowering effects were also seen when compared to the 10 mg Amlodipine and 80 mg Telmisartan groups. But, when compared to the placebo group, the third-dose group's blood pressure substantially improved. Both the response rates and the control rate of hypertension exhibited a comparable pattern.

After accounting for gender and age variables, more research was carried out. Regarding the blood pressure-reducing effect, the third-dose group's outcomes were comparable to those of the half-dose and quarter-dose arms. All dose groups of the triple combination were reported to be safe for treatment in individuals with essential hypertension as there were no unusual adverse events and no clinically meaningful effects.

People with essential hypertension who took the antihypertensive combination of Amlodipine, Telmisartan, and Chlorthalidone for eight weeks experienced an improvement in their blood pressure-reducing effects without any safety issues.